Global pharmaceutical contract packaging organisation (CPO), Tjoapack has invested in a new packaging line for pre-filled syringes and vials at its production facilities in both Europe and the US.
The recently validated PFS line can pack pre-filled syringes of 1 to 5ml, with or without safety devices, and other customer-specific components can also be added.
The move is in response to customer demand for pre-filled syringes, which is a market expected to grow at a compound annual growth rate (CAGR) of 11.95% from 2022 to 2030.
As part of several recent investments and expansions across the wider business, the CPO said this funding will further enhance its integrated packaging offering.
Marcelo Cruz, vice-president of business development and marketing, said: “The pressure to develop vaccines and treatments for Covid-19 has helped spur strong growth in the pre-filled syringe market.
“As the market expands, this latest investment in our pre-filled syringe line is an important step to meeting the growing needs of our customers.
“Packaging solutions are fundamental to the safe, effective delivery of almost every pharmaceutical product and I am proud that our new pre-filled syringe line will help bring even more products to market safely.”
The CPO, which specialises in primary and secondary packaging of oral solids and injectables, has doubled its capacity with the addition of 10 new production rooms and increased the size of its Netherlands facility from 8,400sqm to 11,500sqm over the past year.
The addition of packaging for PFS complements the recent investments in a fully automated packaging line for vials, with the capacity of packing 12 million vials per year. There are also two new high-speed production lines for oral solids, capable of packing over 500 blisters per minute each. The Tjoapack Netherlands facility now has a total of 18 packaging lines for blisters, vials, and bottles.